Amended Statement of Ownership (sc 13g/a)
May 03 2021 - 12:54PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment No. 1 – Exit Filing)*
Innovation
Pharmaceuticals Inc.
(Name
of Issuer)
|
|
Common
Stock Class A, $0.0001 par value
(Title
of Class of Securities)
|
|
15115V101
(CUSIP
Number)
|
|
April 19, 2021
(Date
of Event Which Requires Filing of this Statement)
|
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
* The remainder of this cover
page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that section of the Act but shall be subject to all other provisions of the Act.
CUSIP NO. 15115V101
|
13G
|
Page
2 of 4 Pages
|
1
|
|
NAME OF REPORTING PERSON:
Kips Bay Select LP
|
|
|
|
2
|
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
|
(a) ☐
|
|
|
|
|
(b) ☐
|
|
|
|
|
|
|
3
|
|
SEC
USE ONLY
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
|
|
|
Delaware
|
|
|
|
|
|
5
|
|
SOLE
VOTING POWER
|
NUMBER
OF
|
|
|
|
21,200,000 shares of Common Stock Class A
|
SHARES
|
|
|
BENEFICIALLY
|
|
6
|
|
SHARED
VOTING POWER
|
OWNED
|
|
|
|
0
|
BY
|
|
|
EACH
|
|
7
|
|
SOLE
DISPOSITIVE POWER
|
REPORTING
|
|
|
|
21,200,000 shares of Common Stock Class A
|
PERSON
|
|
|
WITH:
|
|
8
|
|
SHARED
DISPOSITIVE POWER
|
|
|
|
|
0
|
9
|
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
21,200,000 shares of Common Stock Class A
|
|
|
|
10
|
|
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
|
|
☐
|
|
|
|
|
|
|
11
|
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
4.97%
|
|
|
|
12
|
|
TYPE
OF REPORTING PERSON*
|
|
|
|
|
PN
|
|
|
CUSIP NO. 15115V101
|
13G
|
Page
3 of 4 Pages
|
ITEM
1(a).
|
NAME
OF ISSUER:
|
Innovation
Pharmaceuticals Inc.
ITEM
1(b).
|
ADDRESS
OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
|
301
Edgewater Place, Suite 100
Wakefield,
MA 01880
ITEM
2(a).
|
NAME
OF PERSON FILING:
|
Kips Bay Select LP
ITEM
2(b).
|
ADDRESS
OF PRINCIPAL BUSINESS OFFICE:
|
350 Lincoln Rd.
Miami, FL 33139
Delaware
ITEM
2(d).
|
TITLE
OF CLASS OF SECURITIES:
|
Common Stock Class A, $0.0001 par value
15115V101
ITEM
3.
|
IF
THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
|
Not
applicable.
(a)
|
Amount beneficially owned:
|
21,200,000 shares of Common Stock Class A
|
(b)
|
Percent of class:
|
4.97%
|
(c)
|
Number of shares as to which the person has:
|
|
|
(i)
|
Sole power to vote or to direct the vote:
|
21,200,000 shares of Common Stock Class A
|
|
(ii)
|
Shared power to vote or to direct the vote:
|
0
|
|
(iii)
|
Sole power to dispose or to direct the disposition of:
|
21,200,000 shares of Common Stock Class A
|
|
(iv)
|
Shared power to dispose or to direct the disposition of:
|
0
|
ITEM
5.
|
OWNERSHIP
OF FIVE PERCENT OR LESS OF A CLASS:
|
If
this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial
owner of more than five percent of the class of securities check the following. ☒
ITEM
6.
|
OWNERSHIP
OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
|
Not
applicable.
CUSIP NO. 15115V101
|
13G
|
Page
4 of 4 Pages
|
ITEM
7.
|
IDENTIFICATION
AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
|
Not
applicable.
ITEM
8.
|
IDENTIFICATION
AND CLASSIFICATION OF MEMBERS OF A GROUP:
|
Not
applicable.
ITEM
9.
|
NOTICE
OF DISSOLUTION OF GROUP:
|
Not
applicable.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under §240.14a-11.
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
By:
|
/s/ John Miller
|
|
Name/Title:
|
John Miller/ VP of Finance
|
|
Date:
|
April 30, 2021
|
Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From Nov 2023 to Nov 2024